Serco to carry on managing nuclear bomb facilities
International services firm Serco is to retain its contract to manage and operate the UK Atomic Weapons Establishment - the arm of the military which builds and maintains Britain's nuclear warheads.
International services firm Serco is to retain its contract to manage and operate the UK Atomic Weapons Establishment - the arm of the military which builds and maintains Britain's nuclear warheads.
Serco has had the contract since 2000 - it is worth around £300m per year and the extension will run between 2013 and 2018, adding £1.5bn to the firm's order book.
The work is done in tandem with Lockheed Martin and Jacobs Engineering Group.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Christopher Hyman, Chief Executive of Serco, said: "We are delighted to have successfully agreed this latest pricing period for our AWE contract.
"Working closely with the Ministry of Defence and our joint venture partners, we are delivering a critical component of national security and providing leading scientific research as well as delivering value for money for the taxpayer," he said.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Doug and Mary Perkins: Specsavers’ clear-sighted founders
Helped by the deregulation of the sector in the 1980s and brilliant advertising, Mary Perkins and her husband Doug have taken Specsavers to the top of the optometry market
-
Cash in on the biotech boom with three promising European picks
Opinion Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d put their money